


REMARKS

The subject case is a PCT application entering the US National Phase under 35 U.S.C. § 371 and Article 39(1)(a) of the Patent Cooperation Treaty.

Claims 4, 10, and 16 have been amended by inserting the specific PPAR agonists that are listed in the table on page 11 of the application. The amendment is therefore well supported.

Applicants respectfully request substantive examination of the claims. If the Examiner wishes to discuss any matter relating to this application, the Examiner is invited to telephone the undersigned attorney at the number below.

Respectfully submitted,

By 
James L. McGinnis
Reg. No. 34,387
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0641

Date: February 14, 2005